

Desmond Yip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3739185/publications.pdf>

Version: 2024-02-01

173
papers

3,992
citations

117571

34
h-index

149623

56
g-index

179
all docs

179
docs citations

179
times ranked

6890
citing authors

#	ARTICLE	IF	CITATIONS
1	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. <i>European Journal of Cancer</i> , 2015, 51, 1405-1414.	1.3	283
2	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
3	Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1182-1192.	3.0	119
4	Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 217-225.	0.8	118
5	LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. <i>Scientific Reports</i> , 2018, 8, 73.	1.6	112
6	A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. <i>BMC Cancer</i> , 2005, 5, 132.	1.1	105
7	Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. , 2006, , CD002093.		102
8	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	1.3	97
9	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
10	Predictive and prognostic factors in small cell lung cancer: current status. <i>Lung Cancer</i> , 2000, 28, 173-185.	0.9	86
11	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	1.3	84
12	Management of metastatic carcinoma of the uveal tract: an evidence-based analysis. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 553-565.	1.3	82
13	Chemotherapy and radiotherapy for advanced pancreatic cancer. <i>The Cochrane Library</i> , 2018, 2018, CD011044.	1.5	80
14	Matrix metalloproteinase inhibitors: applications in oncology. <i>Investigational New Drugs</i> , 1999, 17, 387-399.	1.2	79
15	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , 2018, 57, 1438-1444.	0.8	78
16	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
17	Recent advances in management of small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 521-543.	3.4	69
18	Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. <i>Internal Medicine Journal</i> , 2005, 35, 222-227.	0.5	65

#	ARTICLE	IF	CITATIONS
19	Radioembolization in Combination with Systemic Chemotherapy as First-line Therapy for Liver Metastases from Colorectal Cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 780-786.	0.2	64
20	Management of Small Cell Lung Cancer. <i>Drugs</i> , 2012, 72, 471-490.	4.9	63
21	RADIATION-INDUCED ULCERATION OF THE STOMACH SECONDARY TO HEPATIC EMBOLIZATION WITH RADIOACTIVE YTTRIUM MICROSPHERES IN THE TREATMENT OF METASTATIC COLON CANCER. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 347-349.	1.4	62
22	Telehealth in cancer care: during and beyond the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2021, 51, 125-133.	0.5	59
23	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. <i>Annals of Oncology</i> , 2014, 25, 117-121.	0.6	57
24	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020, 16, 467-482.	1.4	56
25	A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. <i>Annals of Oncology</i> , 2001, 12, 1399-1402.	0.6	51
26	Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report. <i>BMC Cancer</i> , 2004, 4, 74.	1.1	51
27	Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch. <i>Frontiers in Immunology</i> , 2020, 11, 1228.	2.2	49
28	Differential Roles for DUSP Family Members in Epithelial-to-Mesenchymal Transition and Cancer Stem Cell Regulation in Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0148065.	1.1	48
29	Thymoma and agranulocytosis: two case reports and literature review. <i>British Journal of Haematology</i> , 1996, 95, 52-56.	1.2	46
30	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, e9-e15.	1.0	45
31	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 483-497.	2.0	41
32	Uptake and adherence to an online intervention for cancer-related distress: older age is not a barrier to adherence but may be a barrier to uptake. <i>Supportive Care in Cancer</i> , 2017, 25, 1905-1914.	1.0	41
33	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	2.6	39
34	Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. <i>Lancet Oncology</i> , The, 2005, 6, 724-727.	5.1	38
35	A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors. <i>PeerJ</i> , 2016, 4, e2613.	0.9	38
36	Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up*. <i>Internal Medicine Journal</i> , 2003, 33, 427-435.	0.5	34

#	ARTICLE	IF	CITATIONS
37	Developing a national database for metastatic colorectal cancer management: perspectives and challenges. <i>Internal Medicine Journal</i> , 2013, 43, 1224-1231.	0.5	33
38	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). <i>Journal of Clinical Oncology</i> , 2021, 39, 990-1000.	0.8	30
39	PET and PLAP in suspected testicular cancer relapse: Beware sarcoidosis. <i>Annals of Oncology</i> , 2001, 12, 1485-1488.	0.6	28
40	New KRAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e52-e56.	0.8	28
41	Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy. <i>Cancer Science</i> , 2018, 109, 3383-3392.	1.7	28
42	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	2.3	28
43	A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 401-412.	0.9	27
44	Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 226-238.	0.7	26
45	Finding My Way: results of a multicentre RCT evaluating a web-based self-guided psychosocial intervention for newly diagnosed cancer survivors. <i>Supportive Care in Cancer</i> , 2019, 27, 2533-2544.	1.0	25
46	Omeprazole-Induced Interstitial Nephritis. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 450-452.	1.1	25
47	Gastrointestinal Stromal Tumors. , 2011, , 139-172.		25
48	Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. <i>The Cochrane Library</i> , 2009, , CD002093.	1.5	24
49	Universal molecular screening does not effectively detect Lynch syndrome in clinical practice. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 361-371.	1.4	24
50	A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4-4.	0.8	24
51	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015, 51, 852-860.	1.3	23
52	Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?. <i>Chronobiology International</i> , 2017, 34, 492-503.	0.9	23
53	Personalising pancreas cancer treatment: When tissue is the issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7849.	1.4	22
54	Immunomodulation therapy in colorectal carcinoma. <i>Cancer Treatment Reviews</i> , 2000, 26, 169-190.	3.4	20

#	ARTICLE	IF	CITATIONS
55	Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. <i>Journal of Geriatric Oncology</i> , 2015, 6, 387-394.	0.5	20
56	Does low volume high-intensity interval training elicit superior benefits to continuous low to moderate-intensity training in cancer survivors?. <i>World Journal of Clinical Oncology</i> , 2018, 9, 1-12.	0.9	20
57	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
58	Advances in adjuvant systemic therapy for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 633.	0.9	19
59	Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 26-30.	0.7	18
60	Finding My Way: protocol of a randomised controlled trial evaluating an internet self-help program for cancer-related distress. <i>BMC Cancer</i> , 2015, 15, 328.	1.1	17
61	Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. <i>ANZ Journal of Surgery</i> , 2004, 74, 951-956.	0.3	16
62	Docetaxel-induced nasal septal perforation. <i>Internal Medicine Journal</i> , 2006, 36, 471-472.	0.5	16
63	Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy. <i>Cancer Medicine</i> , 2020, 9, 9027-9035.	1.3	16
64	Hepatocellular carcinoma in central Sydney: a 10 year review of patients seen in a medical oncology department. <i>World Journal of Gastroenterology</i> , 1999, 5, 483.	1.4	16
65	Numb chin syndrome: A case series of a clinical syndrome associated with malignancy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 700-705.	0.9	15
66	Regorafenib-induced hyperammonemic encephalopathy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 446-448.	0.7	15
67	Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma. <i>Internal Medicine Journal</i> , 2016, 46, 1291-1297.	0.5	15
68	Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: Clinical and pathologic findings. <i>Asian Journal of Surgery</i> , 2016, 39, 144-148.	0.2	15
69	Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3080.	1.8	15
70	Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. <i>World Journal of Gastroenterology</i> , 2017, 23, 2276.	1.4	13
71	Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH. <i>Pathology</i> , 2009, 41, 356-360.	0.3	12
72	The changing face of GIST: implications for pathologists. <i>Pathology</i> , 2014, 46, 141-148.	0.3	12

#	ARTICLE	IF	CITATIONS
73	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046.	1.4	12
74	Patterns of care for metastatic renal cell carcinoma in Australia. <i>BJU International</i> , 2015, 116, 36-41.	1.3	12
75	Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 136-143.	0.7	12
76	Routine screening of Indigenous cancer patientsâ€™ unmet support needs: a qualitative study of patient and clinician attitudes. <i>International Journal for Equity in Health</i> , 2016, 15, 90.	1.5	11
77	How does the gut microbiome influence immune checkpoint blockade therapy?. <i>Immunology and Cell Biology</i> , 2021, 99, 361-372.	1.0	11
78	Metastectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100637.	1.0	11
79	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3521-3521.	0.8	11
80	Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. <i>World Journal of Clinical Oncology</i> , 2019, 10, 350-357.	0.9	11
81	Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. <i>Gynecologic Oncology</i> , 2006, 103, 439-445.	0.6	10
82	Serious hepatic complications of selective internal radiation therapy with yttriumâ€™90 microsphere radioembolization for unresectable liver tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 266-272.	0.7	10
83	Indigenous cancer patient and staff attitudes towards unmet needs screening using the SCNAT-IP. <i>Supportive Care in Cancer</i> , 2016, 24, 215-223.	1.0	10
84	Local Recurrence after Mastectomy and Adjuvant CMF: Implications for Adjuvant Radiation Therapy. <i>ANZ Journal of Surgery</i> , 2000, 70, 649-655.	0.3	9
85	How well informed is the informed consent for cancer clinical trials?. <i>Clinical Trials</i> , 2014, 11, 686-688.	0.7	9
86	Geriatric assessment of older patients with cancer in Australiaâ€™A multicentre audit. <i>Journal of Geriatric Oncology</i> , 2015, 6, 185-193.	0.5	9
87	Prognostic significance of <i>KIT</i> exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 115-124.	0.7	9
88	A Rapid Access Clinic to improve delivery of ambulatory care to cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 179-184.	0.7	9
89	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11023-11023.	0.8	9
90	New systemic treatment options for metastatic renalâ€™cell carcinoma in the era of targeted therapies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 5-18.	0.7	8

#	ARTICLE	IF	CITATIONS
91	The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. <i>Acta Oncologica</i> , 2014, 53, 877-884.	0.8	8
92	Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e133-40.	0.7	8
93	Combined immune therapy grade IV dermatitis in metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 262-265.	0.7	8
94	Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. <i>World Journal of Hepatology</i> , 2021, 13, 1132-1142.	0.8	8
95	Simple and effective bacterial-based intratumoral cancer immunotherapy. , 2021, 9, e002688.		8
96	A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies. <i>Annals of Oncology</i> , 2003, 14, 864-866.	0.6	7
97	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 314-321.	0.7	7
98	Management of metastatic renal cell carcinoma in the era of targeted therapies. <i>Internal Medicine Journal</i> , 2011, 41, 594-605.	0.5	6
99	Controversies in the management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 216-227.	0.7	6
100	Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 262-271.	0.7	6
101	Australia and New Zealand's responsibilities in improving oncology services in the Asia-Pacific: A call to action. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	6
102	The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3560-3560.	0.8	6
103	A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 298-305.	0.7	5
104	Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions. <i>Internal Medicine Journal</i> , 2014, 44, 442-449.	0.5	5
105	Application of hypersensitivity skin testing in chemotherapy-induced pneumonitis. <i>Asia Pacific Allergy</i> , 2015, 5, 234-236.	0.6	5
106	Massive fatal pulmonary haemorrhage during bevacizumab treatment following microwave ablation therapy for oligometastatic lung metastasis from rectal cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 26, 514-515.	0.5	5
107	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
108	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	2.9	5

#	ARTICLE	IF	CITATIONS
109	Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer. <i>Healthcare (Switzerland)</i> , 2021, 9, 778.	1.0	5
110	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3511-3511.	0.8	5
111	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3518.	0.8	5
112	Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. <i>World Journal of Gastroenterology</i> , 2015, 21, 5352.	1.4	5
113	ESMO localised colon cancer guidelines: "can we improve on our surveillance protocols"? <i>Annals of Oncology</i> , 2020, 31, 1778-1779.	0.6	4
114	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021, 20, e21-e34.	1.0	4
115	Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours. <i>Internal Medicine Journal</i> , 2021, 51, 955-959.	0.5	4
116	Consensus approaches to best practice management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 188-198.	0.7	3
117	Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. <i>Internal Medicine Journal</i> , 2018, 48, 637-644.	0.5	3
118	Considerations for cancer immunotherapy during the COVID-19 pandemic. <i>Medical Journal of Australia</i> , 2020, 213, 390.	0.8	3
119	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	1.7	3
120	Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	3
121	Survival benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma: A systematic review of the literature.. <i>Journal of Clinical Oncology</i> , 2014, 32, 296-296.	0.8	3
122	Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e055322.	0.8	3
123	Selective Targeting of Protein Kinase C (PKC)- δ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. <i>Cancers</i> , 2022, 14, 1596.	1.7	3
124	Adjuvant chemotherapy for node-positive breast cancer: a retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil. <i>Breast</i> , 1999, 8, 28-34.	0.9	2
125	Epirubicin, Cisplatin, and Prolonged or Brief Infusional 5-Fluorouracil in the Treatment of Carcinoma of Unknown Primary Site. <i>Medical Oncology</i> , 2001, 18, 23-32.	1.2	2
126	Evidence supports adjuvant radiotherapy in selected patients with rectal cancer. <i>ANZ Journal of Surgery</i> , 2004, 74, 152-157.	0.3	2

#	ARTICLE	IF	CITATIONS
127	Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2005, 31, 236-241.	3.4	2
128	Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 170-174.	0.7	2
129	Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missense mutations. <i>Pathology</i> , 2013, 45, 604-606.	0.3	2
130	The challenge of managing adrenocortical carcinoma: two case studies. <i>International Journal of Endocrine Oncology</i> , 2015, 2, 175-184.	0.4	2
131	Identifying women at risk of weight gain after a breast cancer diagnosis: Results from a cohort of Australian women. <i>Health Promotion Journal of Australia</i> , 2022, 33, 138-147.	0.6	2
132	Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.. <i>Journal of Clinical Oncology</i> , 2016, 34, 650-650.	0.8	2
133	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. <i>Targeted Oncology</i> , 2022, 17, 95.	1.7	2
134	A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
135	Cancer in the elderly: gathering the evidence. <i>Medical Journal of Australia</i> , 1999, 170, 577-578.	0.8	1
136	Management of small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 197-210.	1.1	1
137	The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 187-192.	0.7	1
138	Immune modulation via epigenetic targeting to overcome immune checkpoint inhibitor resistance. <i>Immunotherapy</i> , 2019, 11, 1263-1266.	1.0	1
139	Psychometric Assessment of the Malay Version of the 14-Item Resilience Scale (RS-14) in Women With Breast Cancer. <i>Journal of Nursing Measurement</i> , 2021, 29, E18-E38.	0.2	1
140	A collaborative approach to meeting oncology challenges in island communities in the Asia-Pacific region. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 418-423.	0.9	1
141	Role of direct oral anticoagulants in gastrointestinal cancer associated thrombosis –practical issues in clinical practice” narrative review. <i>Annals of Palliative Medicine</i> , 2021, 10, 10053-10061.	0.5	1
142	The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3588-3588.	0.8	1
143	Evaluation of a web-based cognitive rehabilitation programme (CRP) in cancer survivors reporting cognitive symptoms following chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9510-9510.	0.8	1
144	Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease.. <i>Journal of Clinical Oncology</i> , 2017, 35, 682-682.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. Journal of Clinical Oncology, 2017, 35, 750-750.	0.8	1
146	Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3531-3531.	0.8	1
147	Left- versus right-side metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.. Journal of Clinical Oncology, 2019, 37, 623-623.	0.8	1
148	Answering real-world questions using real-world data: Understanding dynamic treatment decisions and outcomes in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, e18061-e18061.	0.8	1
149	Prediction models for venous thromboembolism in ambulatory adults with pancreatic and gastro-oesophageal cancer: protocol for systematic review and meta-analysis. BMJ Open, 2022, 12, e056431.	0.8	1
150	PREOPANC Trial: Survival in the Control Arm and Role of Radiation Need More Explanation. Journal of Clinical Oncology, 0, , .	0.8	1
151	Recent onset granulomatous common variable immunodeficiency in an 88-year-old woman. Pathology, 2003, 35, 81-83.	0.3	0
152	Australian patterns of practice survey in the adjuvant systemic treatment of early breast cancer. Asia-Pacific Journal of Clinical Oncology, 2005, 1, 25-33.	0.7	0
153	New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma. , 0, , .		0
154	Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer. The Cochrane Library, 0, , .	1.5	0
155	How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e167-e174.	0.7	0
156	GEP-NET: Knowledge gaps in the recent ESMO Guidelines. Annals of Oncology, 2020, 31, 1260-1261.	0.6	0
157	Survival and Outcomes After Noncompletion of Treatment for Anal Cancer. JAMA Oncology, 2020, 6, 1977.	3.4	0
158	Neoadjuvant Chemotherapy in Pancreatic Cancer. JAMA Surgery, 2021, 156, 396.	2.2	0
159	Oncological Emergencies: Diagnosis and Management. , 2009, , 201-229.		0
160	Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study.. Journal of Clinical Oncology, 2011, 29, 3602-3602.	0.8	0
161	Geriatric assessment (GA) of older patients with cancer in Australia: A national, multicenter audit.. Journal of Clinical Oncology, 2011, 29, 9134-9134.	0.8	0
162	Single institutional series of neuroendocrine tumours managed in the Australian capital territory.. Journal of Clinical Oncology, 2012, 30, e14703-e14703.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Results of Australasian Gastrointestinal Trials Group (AGITG) Arctic study: An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines (FP).. Journal of Clinical Oncology, 2012, 30, e13007-e13007.	0.8	0
164	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. Journal of Clinical Oncology, 2013, 31, 534-534.	0.8	0
165	First-line clinical trials and metastatic colorectal cancer: How selected are clinical trial participants?. Journal of Clinical Oncology, 2013, 31, 524-524.	0.8	0
166	Effects of adjuvant trastuzumab with chemotherapy (ATWC) in T1N0 HER2 positive (HER2+) breast cancer.. Journal of Clinical Oncology, 2015, 33, e11595-e11595.	0.8	0
167	Association between type 2 diabetes mellitus (T2DM), diabetic therapies and clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, e14637-e14637.	0.8	0
168	Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia.. Journal of Clinical Oncology, 2015, 33, e14648-e14648.	0.8	0
169	Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2017, 35, 728-728.	0.8	0
170	A real-world registry to evaluate HER2-directed therapy in Australian patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, e12515-e12515.	0.8	0
171	Use and impact of perioperative chemotherapy in patients with resectable colorectal cancer metastases.. Journal of Clinical Oncology, 2020, 38, 159-159.	0.8	0
172	Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 605-613.	0.7	0
173	Recent onset granulomatous common variable immunodeficiency in an 88-year-old woman. Pathology, 2003, 35, 81-3.	0.3	0